Key Highlights

  • Revenue was USD 9.53 million against an estimate of USD 9.85 million.
  • Loss per share was USD 0.23 against an estimate of a USD 0.21 loss.
  • Net loss was USD 11.27 million, compared with USD 11.51 million.
  • Cash and cash equivalents were USD 6.62 million at September 30, 2026.

Rapid Micro Biosystems (NASDAQ:RPID) reported Revenue of USD 9.53 million for the third quarter of 2026, compared with USD 7.84 million in the prior-year quarter, against an estimate of USD 9.85 million. Basic and diluted net loss per share was USD 0.23, compared with USD 0.26, against an estimate of a USD 0.21 loss.

Net loss was USD 11.27 million, compared with USD 11.51 million. The company's results were presented in thousands of U.S. dollars.

Third Quarter Results

Product revenue was USD 6.51 million, compared with USD 5.21 million, and service revenue was USD 3.01 million, compared with USD 2.62 million. Total cost of revenue was USD 7.13 million, compared with USD 7.14 million, and gross Margin was USD 2.40 million, compared with USD 696 thousand.

Research and development expenses were USD 2.97 million, compared with USD 3.53 million, and sales and Marketing expenses were USD 3.02 million, compared with USD 2.90 million. General and administrative expenses were USD 6.33 million, compared with USD 5.64 million. The company also reported restructuring expense of USD 721 thousand. Total operating expenses were USD 13.04 million, compared with USD 12.07 million.

Loss and Nine-Month Results

The loss from operations was USD 10.64 million, compared with USD 11.37 million. Interest income was USD 98 thousand, compared with USD 347 thousand, and interest expense was USD 632 thousand, compared with USD 393 thousand. Total other expense, net, was USD 608 thousand, and the loss before income taxes was USD 11.25 million. Weighted average common shares outstanding were 48,875,933, compared with 44,956,131.

For the nine months, revenue was USD 25.58 million, compared with USD 22.31 million, and gross margin was USD 3.99 million, compared with USD 1.38 million. The loss from operations was USD 36.81 million, compared with USD 35.18 million, and the net loss was USD 38.47 million, compared with USD 34.63 million. Net loss per share for the nine months was USD 0.79, compared with USD 0.78.

Balance Sheet

Cash and cash equivalents were USD 6.62 million at September 30, 2026, compared with USD 20.03 million at December 31, 2025. Short-term investments were USD 102 thousand, compared with USD 18.27 million. Total Assets were USD 47.57 million, compared with USD 74.85 million.

Total liabilities were USD 38.76 million, compared with USD 41.65 million, and total stockholders' Equity was USD 8.81 million, compared with USD 33.21 million.

The company describes itself as a life sciences technology company providing automation solutions for the Manufacturing and release of healthcare products such as biologics, vaccines, cell and gene therapies and sterile injectables. Total current assets were USD 36.32 million, compared with USD 61.17 million, and property and equipment, net, was USD 7.55 million, compared with USD 8.97 million.

Rapid Micro Biosystems Q3 2026 Earnings: Key Takeaways

Rapid Micro Biosystems reported third quarter 2026 revenue of USD 9.53 million and a net loss of USD 11.27 million. Cash and cash equivalents were USD 6.62 million and total stockholders' equity was USD 8.81 million at September 30, 2026.